Arcus Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Arcus Biosciences generated cash of -$306,000,000, which is less than the previous year. Cash used in financing activities reached the amount of $33,000,000 last year. Net change in cash is therefore -$79,000,000.
Cash Flow
| 2016 | -12.94M | -38.86M | 70.1M |
|---|---|---|---|
| 2017 | -25.05M | -49.07M | 107.39M |
| 2018 | -42.99M | -113.44M | 129.07M |
| 2019 | -73.46M | 59.21M | 1.12M |
| 2020 | 111.17M | -434.36M | 438.67M |
| 2021 | -256.17M | -3.86M | 237.34M |
| 2022 | 438M | -413M | 33M |
| 2023 | -306M | 194M | 33M |
RCUS Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 209M | 151M | 173.61M | 58.14M | 71.26M | 98.42M | 65.16M | 46.86M |
Operating activities | ||||||||
Net income | -307M | -267M | 52.83M | -122.85M | -84.71M | -49.59M | -53.08M | -17.97M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 8M | 6M | 3.84M | 4.19M | 3.57M | 3.66M | 2.61M | 1.31M |
Stock-based compensation expense | 73M | 65M | 55M | 22M | 8.98M | 0 | 495K | 90K |
| Deferred income tax benefit | 73M | 65M | 55M | 22M | 8.98M | 0 | 495K | 90K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 15M | 704M | -17.04M | -917K | -132K | 0 | 380K | 0 |
Inventories | 0 | -704M | 14.08M | 21.32M | 1.06M | 0 | 0 | 0 |
Accounts payable | -1M | 8M | -4.77M | 9.27M | 1.72M | -69K | -267K | 3.56M |
Cash generated by operating activities | -306M | 438M | -256.17M | 111.17M | -73.46M | -42.99M | -25.05M | -12.94M |
Investing activities | ||||||||
Purchases Of Investments | -788M | -1.24B | -718.86M | -739.65M | -247.75M | -261.55M | -96.83M | -33.76M |
Investments In Property Plant And Equipment | -24M | -12M | -26.07M | -3.05M | -1.92M | -3.74M | -5.51M | -4.09M |
Acquisitions Net | 0 | 0 | -22M | 431M | -61.13M | 0 | 0 | -1M |
Cash generated by investing activities | 194M | -413M | -3.86M | -434.36M | 59.21M | -113.44M | -49.07M | -38.86M |
Financing activities | ||||||||
Common Stock Issued | 25M | 23M | 220.23M | 433.77M | 1.21M | 125.11M | 892K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -6K | -54K | -94K | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -5M | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 33M | 33M | 237.34M | 438.67M | 1.12M | 129.07M | 107.39M | 70.1M |
Net Change In Cash | -79M | 58M | -22.69M | 115.47M | -13.12M | -27.36M | 33.26M | 18.29M |
Cash at end of period | 130M | 209M | 150.91M | 173.61M | 58.14M | 71.06M | 98.42M | 65.16M |
| Data source | Data source | Data source | Data source | Data source | Data source |